search
Back to results

Aerobic Exercise Training in Patients With Chronic Hepatitis B and Hepatic Steatosis (FitLiver)

Primary Purpose

Hepatitis B, Chronic, Hepatic Steatosis

Status
Active
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
High Intensity Interval Training
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatitis B, Chronic

Eligibility Criteria

30 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Chronic hepatitis B defined by HBsAg positive >6 months
  • Positive HBV-DNA
  • Age >30
  • Hepatic steatosis diagnosed by Controlled Attenuated Parameter (CAP) >250 assessed by Transient Elastography or by ultrasound defined hepatic steatosis

Exclusion Criteria:

  • HIV, HCV, HDV-co infection
  • Primary biliary cholangitis
  • Wilsons Disease
  • Autoimmune hepatitis
  • Hepatocellular carcinoma
  • Antiviral medication
  • Steatogenic medication (systemic corticosteroids, amiodarone, tamoxifen, valproic acid, and methotrexate)
  • Average alcohol intake >30 g for men and >20 g for women pr. day
  • Unable to understand and read written information for participants written consent
  • Pregnancy

Sites / Locations

  • Centre for Physical Activity Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Exercise Intervention Arm

No Intervention

Arm Description

Three high intensity interval exercise sessions per week of 40 minutes duration per session. Exercise will be performed on ergometerbikes.

No lifestyle changes

Outcomes

Primary Outcome Measures

Fat-Fraction of the Liver
Hepatic fat-fraction measured by MRI with IDEAL-IQ (%)

Secondary Outcome Measures

Fibroblast growth factor 21 (FGF21) secretion
FGF21 (ng/L) secretion during a hormone infusion of somatostatin and glucagon
Follistatin secretion
Follistatin (ng/L) secretion during a hormone infusion of somatostatin and glucagon
Growth/differentiation factor 15 (GDF15) secretion
GDF15 (ng/L) secretion during a hormone infusion of somatostatin and glucagon
Angiopoietin-like 4 (ANGPTL4) secretion
ANGPTL4 (μg/L) secretion during a hormone infusion of somatostatin and glucagon
C-reactive protein (CRP) secretion
CRP (mg/L) secretion during a hormone infusion of somatostatin and glucagon
Interferon-ϒ secretion
Interferon-ϒ (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Interleukin-10 secretion
Interleukin-10 (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Interleukin-8 secretion
Interleukin-8 (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Interleukin-6 secretion
Interleukin-6 (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Interleukin-1 secretion
Interleukin-1 (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
TNFα secretion
TNFα (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Visceral fat
Visceral fat assessed by MRI (kg)
Total fat mass
Total fat mass assessed by DXA scan (kg)
Total free fat mass
Total free fat mass assessed by DXA scan (kg)
Total lean body mass
Total lean body mass assessed by DXA scan (kg)
Body weight
Body weight (kg)
Blood pressure measurements
Systolic blood pressure (mmHg) and diastolic blood pressure (mmHg)
Physical fitness (VO2max)
Physical fitness assessed by VO2max (mL/kg/min)
Total physical activity
Total physical activity assessed by activity monitor (hours, minutes)
Moderate and vigorous physical activity (MVPA)
Moderate and vigorous physical activity (MVPA) activity monitor (hours, minutes)
Sedentary time (SED)
Sedentary time (SED) activity monitor (hours, minutes)
Hepatitis B virus (DNA)
Hepatitis B virus (DNA) (IU/mL)
Oral glucose tolerance test
Oral glucose tolerance test (mmol/L)
Glycated haemoglobin type 1AC (HbA1c)
Glycated haemoglobin type 1AC (HbA1c) (mmol/mL)
Fasting glucose
Fasting glucose (mmol/L)
Fasting Insulin
Fasting Insulin (pmol/L)
Lipid measurements
Total cholesterol (mmol/L), total triglyceride (mmol/L), low density lipoprotein (LDL) (mmol/L), high density lipoprotein (HDL) (mmol/L)
Alanine transaminase (ALT)
Alanine transaminase (ALT) (U/L)
Aspartate transaminase (AST)
Aspartate transaminase (AST) (U/L)
Fibrosis-4 (FIB-4)
Fibrosis-4 (FIB-4)
International Normalised Ratio (INR)
International Normalised Ratio (INR)

Full Information

First Posted
February 11, 2022
Last Updated
August 4, 2023
Sponsor
Rigshospitalet, Denmark
Collaborators
Copenhagen University Hospital, Hvidovre
search

1. Study Identification

Unique Protocol Identification Number
NCT05265026
Brief Title
Aerobic Exercise Training in Patients With Chronic Hepatitis B and Hepatic Steatosis
Acronym
FitLiver
Official Title
Effect of Aerobic Exercise Training on Fat-fraction of the Liver in Patients With Chronic Hepatitis B and Hepatic Steatosis: a Randomised Controlled Intervention Trial. The Fit Liver Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 14, 2022 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
October 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark
Collaborators
Copenhagen University Hospital, Hvidovre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a randomised, controlled, unblinded, clinical intervention trial consisting of 12 weeks of aerobic exercise training. Thirty persons with chronic hepatitis B (CHB) and hepatic steatosis are randomised to either aerobic exercise training (intervention group, n=15) or no intervention (control group, n=15). The study will investigate the effects of the exercise intervention on the liver and the hypothesis is that the exercise group will reduce the fat-fraction of the liver after the intervention.
Detailed Description
Primary aim: To investigate whether regular aerobic exercise training will decrease the fat-fraction of the liver in persons with CHB and hepatic steatosis shown by magnetic resonance imaging (MRI) by use of Iterative Decomposition of water and fat with Echo Asymmetry and Least squares estimation (IDEAL-IQ). Secondary aim: To investigate the effects of aerobic exercise training on hepatokine secretion in persons with CHB and hepatic steatosis. Also, to investigate if regular physical exercise will improve lipid- and glucose metabolism, liver status, markers of inflammation, body composition, and blood pressure. Study participants will undergo pre and post the interventioon: Clinical examination with ECG, blood pressure measurements, blood sampling, oral glucose tolerance test, a hormone infusion of somatostatin and glucagon, -increasing the glucagon/insulin ratio mimicking an acute exercise bout, measuring the effect on circulating hepatokines and cytokines, fibroscan, VO2-max test, DXA scan, AX3 activity monitoring, nail fold capillaryscopy, IQOLA SF-36 and IPAQ-SF questionnaire, 24H food intake registration, MRI scan of the liver and optional liver biopsy. 6 and 12 months follow-up is planned. The exercise intervention will be randomised 1:1 with no stratification: The training program includes three weekly supervised training sessions of 40 minutes/session over 12 weeks. Participants are instructed not to change their lifestyles during the intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis B, Chronic, Hepatic Steatosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exercise Intervention Arm
Arm Type
Experimental
Arm Description
Three high intensity interval exercise sessions per week of 40 minutes duration per session. Exercise will be performed on ergometerbikes.
Arm Title
No Intervention
Arm Type
No Intervention
Arm Description
No lifestyle changes
Intervention Type
Behavioral
Intervention Name(s)
High Intensity Interval Training
Intervention Description
A training session consists of 40 minutes as follows: 4x4 minutes at > 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-79% of HRmax) and 5- minute cool-down at ~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: >85% of HRmax).
Primary Outcome Measure Information:
Title
Fat-Fraction of the Liver
Description
Hepatic fat-fraction measured by MRI with IDEAL-IQ (%)
Time Frame
From baseline to follow-up at 12 weeks
Secondary Outcome Measure Information:
Title
Fibroblast growth factor 21 (FGF21) secretion
Description
FGF21 (ng/L) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
Follistatin secretion
Description
Follistatin (ng/L) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
Growth/differentiation factor 15 (GDF15) secretion
Description
GDF15 (ng/L) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
Angiopoietin-like 4 (ANGPTL4) secretion
Description
ANGPTL4 (μg/L) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
C-reactive protein (CRP) secretion
Description
CRP (mg/L) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
Interferon-ϒ secretion
Description
Interferon-ϒ (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
Interleukin-10 secretion
Description
Interleukin-10 (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
Interleukin-8 secretion
Description
Interleukin-8 (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
Interleukin-6 secretion
Description
Interleukin-6 (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
Interleukin-1 secretion
Description
Interleukin-1 (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
TNFα secretion
Description
TNFα (pg/mL) secretion during a hormone infusion of somatostatin and glucagon
Time Frame
From baseline to follow-up at 12 weeks
Title
Visceral fat
Description
Visceral fat assessed by MRI (kg)
Time Frame
From baseline to follow-up at 12 weeks
Title
Total fat mass
Description
Total fat mass assessed by DXA scan (kg)
Time Frame
From baseline to follow-up at 12 weeks
Title
Total free fat mass
Description
Total free fat mass assessed by DXA scan (kg)
Time Frame
From baseline to follow-up at 12 weeks
Title
Total lean body mass
Description
Total lean body mass assessed by DXA scan (kg)
Time Frame
From baseline to follow-up at 12 weeks
Title
Body weight
Description
Body weight (kg)
Time Frame
From baseline to follow-up at 12 weeks
Title
Blood pressure measurements
Description
Systolic blood pressure (mmHg) and diastolic blood pressure (mmHg)
Time Frame
From baseline to follow-up at 12 weeks
Title
Physical fitness (VO2max)
Description
Physical fitness assessed by VO2max (mL/kg/min)
Time Frame
From baseline to follow-up at 12 weeks
Title
Total physical activity
Description
Total physical activity assessed by activity monitor (hours, minutes)
Time Frame
From baseline, at 6 weeks to follow-up at 12 weeks
Title
Moderate and vigorous physical activity (MVPA)
Description
Moderate and vigorous physical activity (MVPA) activity monitor (hours, minutes)
Time Frame
From baseline, at 6 weeks to follow-up at 12 weeks
Title
Sedentary time (SED)
Description
Sedentary time (SED) activity monitor (hours, minutes)
Time Frame
From baseline, at 6 weeks to follow-up at 12 weeks
Title
Hepatitis B virus (DNA)
Description
Hepatitis B virus (DNA) (IU/mL)
Time Frame
From baseline to follow-up at 12 weeks
Title
Oral glucose tolerance test
Description
Oral glucose tolerance test (mmol/L)
Time Frame
From baseline to follow-up at 12 weeks
Title
Glycated haemoglobin type 1AC (HbA1c)
Description
Glycated haemoglobin type 1AC (HbA1c) (mmol/mL)
Time Frame
From baseline to follow-up at 12 weeks
Title
Fasting glucose
Description
Fasting glucose (mmol/L)
Time Frame
From baseline to follow-up at 12 weeks
Title
Fasting Insulin
Description
Fasting Insulin (pmol/L)
Time Frame
From baseline to follow-up at 12 weeks
Title
Lipid measurements
Description
Total cholesterol (mmol/L), total triglyceride (mmol/L), low density lipoprotein (LDL) (mmol/L), high density lipoprotein (HDL) (mmol/L)
Time Frame
From baseline to follow-up at 12 weeks
Title
Alanine transaminase (ALT)
Description
Alanine transaminase (ALT) (U/L)
Time Frame
From baseline to follow-up at 12 weeks
Title
Aspartate transaminase (AST)
Description
Aspartate transaminase (AST) (U/L)
Time Frame
From baseline to follow-up at 12 weeks
Title
Fibrosis-4 (FIB-4)
Description
Fibrosis-4 (FIB-4)
Time Frame
From baseline to follow-up at 12 weeks
Title
International Normalised Ratio (INR)
Description
International Normalised Ratio (INR)
Time Frame
From baseline to follow-up at 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Chronic hepatitis B defined by HBsAg positive >6 months Positive HBV-DNA Age >30 Hepatic steatosis diagnosed by Controlled Attenuated Parameter (CAP) >250 assessed by Transient Elastography or by ultrasound defined hepatic steatosis Exclusion Criteria: HIV, HCV, HDV-co infection Primary biliary cholangitis Wilsons Disease Autoimmune hepatitis Hepatocellular carcinoma Antiviral medication Steatogenic medication (systemic corticosteroids, amiodarone, tamoxifen, valproic acid, and methotrexate) Average alcohol intake >30 g for men and >20 g for women pr. day Contraindications for MRI scan Coronary artery disease contraindicating HIIT Unable to understand and read written information for participants written consent Pregnancy
Facility Information:
Facility Name
Centre for Physical Activity Research
City
Copenhagen
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
If the data can be fully anonymized then the data can be shared.

Learn more about this trial

Aerobic Exercise Training in Patients With Chronic Hepatitis B and Hepatic Steatosis

We'll reach out to this number within 24 hrs